Early identification of secondary Raynaud phenomenon is essential to treat the underlying disease—most frequently systemic sclerosis (SSc). Integrated therapeutic approaches and monitoring systems that offer improved modalities of care feature in the new best practice recommendations for the treatment of digital vasculopathy in SSc.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis
Arthritis Research & Therapy Open Access 20 March 2017
-
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study
Arthritis Research & Therapy Open Access 06 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hughes, M. et al. Consensus best practice pathway of the UK Systemic Sclerosis Study Group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford) http://dx.doi.org/10.1093/rheumatology/kev201.
Garner, R., Kumari, R., Lanyon, P., Doherty, M. & Zhang, W. Epidemiology prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 5, e006389 (2015).
Nietert, P. J. et al. Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort. Clin. Epidemiol. 7, 161–168 (2015).
Cutolo, M., Pizzorni, C. & Sulli, A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy : comment on the article by Hirschl et al. Arthritis Rheum. 56, 2102–2103 (2007).
Cutolo, M., Sulli, A. & Smith, V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat. Rev. Rheumatol. 6, 578–587 (2010).
Smith, V. et al. Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis. J. Rheumatol. 40, 2023–2028 (2013).
Cutolo, M. Disease modification in systemic sclerosis. Do integrated approaches offer new challenges? Z. Rheumatol. 72, 326–328 (2013).
Avouac, J. & Allanore, Y. Targeted immunotherapies in systemic sclerosis. Clin. Exp. Rheumatol. 32 (2 Suppl. 81), 165–172 (2014).
Korn, J. H. et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50, 3985–3993 (2004).
Cutolo, M. et al. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J. Rheumatol. 41, 881–886 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Cutolo, M., Sulli, A. Optimized treatment algorithms for digital vasculopathy in SSc. Nat Rev Rheumatol 11, 569–571 (2015). https://doi.org/10.1038/nrrheum.2015.111
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.111
This article is cited by
-
Detection of microvascular changes in systemic sclerosis and other rheumatic diseases
Nature Reviews Rheumatology (2021)
-
Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis
Arthritis Research & Therapy (2017)
-
Primary Raynaud’s phenomenon and nailfold videocapillaroscopy: age-related changes in capillary morphology
Clinical Rheumatology (2017)
-
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study
Arthritis Research & Therapy (2016)